<DOC>
	<DOCNO>NCT00828776</DOCNO>
	<brief_summary>The primary objective study ass safety use drug Heparin Sodium , produce Cristália Laboratory , compare drug Liquemine ® , manufacture Roche Laboratory , secondary purpose evaluate non-inferiority clinical test product product comparator pharmacodynamic effect , evidence analyze parameter TTPA Anti-Xa patient chronic renal failure treatment hemodialysis .</brief_summary>
	<brief_title>Pharmacodynamics Non-Clinical Inferiority Heparin Sodium ( Cristália ) Compared With Product Liquemine ( Roche ) Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Adults sex , regardless color social class Age 18 year good clinical medical criterion Patients agree participate sign Informed Consent Insufficient patient chronic renal dialysis schedule ( 3 time per week ) Patients creatinine clearance &lt; 30ml/min Patients indication anticoagulation hemodialysis Patients sensitivity heparin sodium ; Patients hypersensitivity benzyl alcohol Patients history bleed illness change blood coagulation aggravate terminate clinical picture , table gastric ulcer Patients history peptic ulcer Patients body mass index great 30 Cancer patient possibility compromise function variable coagulation Patients period pregnancy delivery Patients genetic abnormality clot system Polytraumatized patient Patients use glucocorticoid least 1 month Patients use anticoagulant Patients high rate bleeding Patients undergo surgery perform less 15 day due risk training hematoma site surgery Hypertension 140/90 mmHg Patients use medication could affect hemostasis Patients use follow medicine : hormonal anti include Ketorolac ; Dextran 40 , ticlopidine clopidogrel , systemic glucocorticoid , thrombolytic agent anticoagulant antiplatelet agent , include antagonist glycoprotein IIb / IIIa .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>TTPa</keyword>
	<keyword>Anti-Xa</keyword>
	<keyword>Adverse Reactions</keyword>
</DOC>